Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 2
2005 3
2006 4
2007 2
2008 2
2009 6
2010 8
2011 10
2012 12
2013 6
2014 11
2015 12
2016 10
2017 7
2018 7
2019 4
2020 11
2021 15
2022 17
2023 12
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.
Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Álvarez-Larrán A, De Stefano V, Guglielmelli P, Palandri F, Passamonti F, Barosi G, Silver RT, Hehlmann R, Kiladjian JJ, Barbui T. Marchetti M, et al. Among authors: alvarez larran a. Lancet Haematol. 2022 Apr;9(4):e301-e311. doi: 10.1016/S2352-3026(22)00046-1. Lancet Haematol. 2022. PMID: 35358444 Review.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larrán A, Patriarca A, Kremyanskaya M, Mead AJ, Akhani S, Sheikine Y, Colak G, Mascarenhas J. Harrison CN, et al. Among authors: alvarez larran a. Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11. Future Oncol. 2022. PMID: 35950489 Free article.
Atrial fibrillation and MPNs.
Alvarez-Larrán A. Alvarez-Larrán A. Ann Hematol. 2018 Apr;97(4):743. doi: 10.1007/s00277-018-3234-8. Epub 2018 Jan 15. Ann Hematol. 2018. PMID: 29335767 Review. No abstract available.
Breakthrough infections in MPN-COVID vaccinated patients.
Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidel FH, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nałęcz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM. Barbui T, et al. Among authors: alvarez larran a. Blood Cancer J. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. Blood Cancer J. 2022. PMID: 36379921 Free PMC article. No abstract available.
Blood cell activation in myeloproliferative neoplasms.
Cervantes F, Arellano-Rodrigo E, Alvarez-Larrán A. Cervantes F, et al. Among authors: alvarez larran a. Haematologica. 2009 Nov;94(11):1484-8. doi: 10.3324/haematol.2009.013375. Haematologica. 2009. PMID: 19880775 Free PMC article. Review.
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Barbui T, Carobbio A, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, Fenili F, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Calabresi L, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Ramundo F, Lunghi F, Scaffidi L, Bucelli C, Cattaneo D, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A, Vannucchi AM. Barbui T, et al. Among authors: alvarez larran a. Ann Hematol. 2024 Feb;103(2):437-442. doi: 10.1007/s00277-023-05577-9. Epub 2023 Dec 7. Ann Hematol. 2024. PMID: 38060001 Clinical Trial.
[Treatment of essential thrombocythemia].
Alvarez-Larrán A, Cervantes F, Besses C. Alvarez-Larrán A, et al. Med Clin (Barc). 2013 Sep 21;141(6):260-4. doi: 10.1016/j.medcli.2013.01.016. Epub 2013 Mar 13. Med Clin (Barc). 2013. PMID: 23490491 Review. Spanish.
Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.
Alvarez-Larrán A, Sant'Antonio E, Harrison C, Kiladjian JJ, Griesshammer M, Mesa R, Ianotto JC, Palandri F, Hernández-Boluda JC, Birgegård G, Nangalia J, Koschmieder S, Rumi E, Barbui T. Alvarez-Larrán A, et al. Lancet Haematol. 2021 Sep;8(9):e658-e665. doi: 10.1016/S2352-3026(21)00204-0. Lancet Haematol. 2021. PMID: 34450103 Review.
How to Treat Essential Thrombocythemia and Polycythemia Vera.
Besses C, Alvarez-Larrán A. Besses C, et al. Among authors: alvarez larran a. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S114-23. doi: 10.1016/j.clml.2016.02.029. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27521307 Review.
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Díaz-González Á, Mora E, Avetisyan G, Furió S, De la Puerta R, Gil JV, Liquori A, Villamón E, García-Hernández C, Santiago M, García-Ruiz C, Llop M, Ferrer-Lores B, Barragán E, García-Palomares S, Mayordomo E, Luna I, Vicente A, Cordón L, Senent L, Álvarez-Larrán A, Cervera J, De la Rubia J, Hernández-Boluda JC, Such E. Díaz-González Á, et al. Among authors: alvarez larran a. Cancers (Basel). 2023 Jun 2;15(11):3039. doi: 10.3390/cancers15113039. Cancers (Basel). 2023. PMID: 37297002 Free PMC article.
140 results